AspenBio Pharma to Present at the 28th Annual Canaccord Adams Global Growth Conference

CASTLE ROCK, CO, Aug 05 (MARKET WIRE) --
AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical
company dedicated to the development of novel drugs and diagnostics for
animals and humans, has been invited to present at the 28th Annual
Canaccord Adams Global Growth Conference to be held at the
InterContinental Boston on August 12-14, 2008.

AspenBio president and CEO, Richard G. Donnelly, is scheduled to present
on Thursday, August 14 at 9:30 a.m. Eastern Time. The presentation will be
available via webcast at
http://www.corporateir.net/ireye/conflobby.zhtml?ticker=APPY&item_id=1887826.

Mr. Donnelly will discuss the continued advancement of AppyScore(TM), the
world's first blood-based screening/triage test for human appendicitis.
The company is currently conducting an 800 patient FDA clinical trial in
preparation for a late 2008 FDA 510(k) filing. He will also update on the
exclusive license and commercialization agreement AspenBio recently signed
with Novartis Animal Health, Inc. for the development and worldwide launch
of AspenBio's novel bovine reproduction drugs, BoviPure LH(TM) and
BoviPure FSH(TM).

About Canaccord Adams

Canaccord Adams is a leading independent financial services firm committed
to fostering the entrepreneurial economy by bringing corporate and
institutional clients unique perspective on global investment
opportunities. With operations in research, sales and trading, and
investment banking, Canaccord's 225 professionals seek out emerging
opportunities in the key sectors of Mining and Metals, Energy, Technology,
Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth.
Located in eight offices internationally, Canaccord's experienced team
generates focused, actionable ideas that identify opportunity and
facilitate growth.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the
discovery; development, manufacture, and marketing of novel proprietary
products, including those that enhance the reproductive efficiency of
animals and that have large worldwide market potential. The company was
originally formed to produce purified proteins for diagnostic applications
and has become a leading supplier of human hormones to many of the
nation's largest medical diagnostic companies and research institutions.
The company has successfully leveraged this foundational science and
technology expertise to rapidly develop an enviable late-stage pipeline
of several novel reproduction hormone analogs for wide-ranging
therapeutic use in animals of economic importance. AspenBio Pharma
continues to advance the development and testing of its two
first-generation blood-based human diagnostic tests designed to rapidly
help diagnose or rule out acute appendicitis in patients complaining of
abdominal pain. For more information, go to www.aspenbiopharma.com.

Forward-Looking Statements

This news release includes "forward-looking statements" of AspenBio
Pharma, Inc. ("APPY") as defined by the Securities and Exchange
Commission (the "SEC"). All statements, other than statements of
historical fact, included in the press release that address activities,
events or developments that APPY believes or anticipates will or may
occur in the future are forward-looking statements. These statements are
based on certain assumptions made based on experience, expected future
developments and other factors APPY believes are appropriate in the
circumstances. Such statements are subject to a number of assumptions,
risks and uncertainties, many of which are beyond the control of APPY.
Investors are cautioned that any such statements are not guarantees of
future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of
many factors, including statements regarding the ability to successfully
complete the development of, obtain FDA approval for, cost effectively
manufacture and generate revenues from the appendicitis test as well as
the animal products under this agreement and other new products, execute
agreements required to successfully advance the company's objectives,
retain the scientific management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment,
fluctuations in sales volumes, obtain and enforce intellectual property
rights, and realization of intangible assets. Furthermore, APPY does not
intend (and is not obligated) to update publicly any forward-looking
statements. The contents of this news release should be considered in
conjunction with the warnings and cautionary statements contained in
APPY's recent filings with the SEC.

For more information contact:

AspenBio Pharma, Inc.
Gregory Pusey
Chairman
Tel 303-722-4008

Investor Relations
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860

Copyright 2008, Market Wire, All rights reserved.

-0-